Peptide Lab HQ Research Guide
Tesamorelin
A research-focused compound profile covering Tesamorelin identity, GHRH analog research, growth hormone signaling, IGF-1 pathway context, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Tesamorelin |
|---|---|
| Research Code / Synonym | TH9507 |
| Compound Type | Synthetic growth hormone-releasing hormone / growth hormone-releasing factor analog |
| CAS Number | 218949-48-5 |
| Amino Acid Length | 44 amino acids with N-terminal modification |
| Research Category | GHRH analog, growth hormone signaling, IGF-1 pathway, visceral adiposity, and metabolic research |
| Molecular Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular Weight | Approximately 5136 g/mol |
| Regulatory Context | Approved product context exists for HIV-associated lipodystrophy; not indicated for general weight-loss management. |
| Appearance | White to off-white lyophilized powder |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Tesamorelin is commonly discussed in research involving GHRH analog activity, pulsatile growth hormone signaling, IGF-1 pathway response, visceral adiposity models, metabolic endpoint tracking, and HIV-associated lipodystrophy study contexts.
GHRH Analog Research
Tesamorelin is studied as a synthetic growth hormone-releasing hormone analog designed to stimulate endogenous growth hormone release through pituitary signaling pathways.
Growth Hormone Signaling
Used in research models involving growth hormone release, downstream endocrine signaling, and hormone-response documentation.
IGF-1 Pathway Context
Relevant to research involving IGF-1 response, endocrine feedback loops, and growth hormone axis observation.
Visceral Adiposity Models
Commonly discussed in study contexts involving abdominal fat, visceral adipose tissue, metabolic markers, and body-composition endpoints.
HIV Lipodystrophy Research
Tesamorelin has an approved-drug research context related to excess abdominal fat in adults with HIV-associated lipodystrophy.
Metabolic Marker Research
Used in research discussions involving lipid markers, glucose-related monitoring, endocrine response, and cardiometabolic documentation.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on model type, compound form, purity, concentration, study duration, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 2 mg Tesamorelin |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 1 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 1 mg/mL, 1 unit equals 0.01 mg / 10 mcg Tesamorelin. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- For higher-concentration preparations, verify that the material is fully dissolved before recording the final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Tesamorelin, also referenced as TH9507 | Tesamorelin is commonly discussed as a stabilized synthetic analogue of growth hormone-releasing hormone in GHRH receptor and endocrine-marker research contexts. |
| GHRH / Pituitary-Axis Research | Growth hormone-releasing hormone pathway context | Commonly discussed in GHRH receptor signaling, anterior pituitary response, growth hormone release, IGF-1 marker tracking, and endocrine-axis research models. |
| Metabolic Research Context | Clinical-study context only | Tesamorelin has been discussed in clinical-study contexts involving body-composition, visceral-fat, lipid-marker, glucose-marker, and metabolic-endpoint observations. These clinical-study contexts are not research-chemical dosing standards. |
| Body-Composition Marker Research | Model-dependent metabolic-marker tracking | Commonly discussed in adipose-tissue, visceral-fat marker, lean-mass marker, lipolysis, triglyceride marker, and cardiometabolic research contexts. |
| Endocrine / IGF-1 Research Context | Experimental and clinical-marker context | Research discussions commonly include GH / IGF-1 axis activity, pituitary response, feedback signaling, glucose tolerance markers, and endocrine safety-marker documentation. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references commonly describe Tesamorelin in microgram-to-milligram examples depending on the research model and preparation format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, clinical-study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 2 mg | 2.0 mL | 1 mg/mL |
| 5 mg | 2.0 mL | 2.5 mg/mL |
| 10 mg | 2.0 mL | 5 mg/mL |
| 20 mg | 3.0 mL | 6.67 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 1 mg/mL | U-100 Unit Reference | Approx. References per 2 mg Vial |
|---|---|---|---|
| 0.1 mg / 100 mcg | 0.10 mL | 10 units | 20 |
| 0.25 mg / 250 mcg | 0.25 mL | 25 units | 8 |
| 0.5 mg / 500 mcg | 0.50 mL | 50 units | 4 |
| 1 mg / 1000 mcg | 1.00 mL | 100 units | 2 |
| 2 mg / 2000 mcg | 2.00 mL | 200 units | 1 |
| 5 mg / 5000 mcg | 5.00 mL | 500 units | 0.4 |
| 10 mg / 10000 mcg | 10.00 mL | 1000 units | 0.2 |
| 20 mg / 20000 mcg | 20.00 mL | 2000 units | 0.1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Low Conversion Reference | Calculation reference only | 0.1 mg reference amount | 10 units / 0.10 mL |
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.25 mg reference amount | 25 units / 0.25 mL |
| Low-to-Mid Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 50 units / 0.50 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 100 units / 1.00 mL |
| Mid-Range Conversion Example | Calculation reference only | 2 mg reference amount | 200 units / 2.00 mL |
| Upper Conversion Example | Calculation reference only | 5 mg reference amount | 500 units / 5.00 mL |
| High Conversion Example | Calculation reference only | 10 mg reference amount | 1000 units / 10.00 mL |
| Preparation-Level Conversion Example | Calculation reference only | 20 mg reference amount | 2000 units / 20.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Endocrine Marker Window | 24–72 hours | May be used for GHRH receptor signaling, pituitary-response markers, GH / IGF-1 pathway documentation, cellular-response, or endocrine-marker observation depending on the model. |
| Acute Endocrine Observation Window | Single session to several days | Used for short-term GH / IGF-1 marker comparison, pituitary-axis response, glucose-marker observation, or early pathway tracking depending on the research design. |
| Short Research Window | 1–4 weeks | May be used for early controlled observation involving endocrine markers, metabolic markers, IGF-1 response, or body-composition model endpoints. |
| Standard Protocol-Style Window | 4–12 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 12–26 weeks or longer | Used when longer documentation is needed for visceral-fat markers, body-composition markers, lipid markers, glucose markers, IGF-1 marker trends, or follow-up comparison. |
| Follow-Up / Washout | 4–12 weeks | Used to document post-study observations, marker return, delayed response patterns, or return-to-baseline data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Tesamorelin, also referenced as TH9507, is commonly discussed in GHRH analog, GHRH receptor, anterior pituitary, growth hormone, IGF-1, endocrine-axis, body-composition, visceral-fat marker, lipid-marker, glucose-marker, and metabolic research contexts. The selector above updates calculations for 2 mg, 5 mg, and 10 mg vial references reconstituted with 2.0 mL bacteriostatic water, and a 20 mg vial reference reconstituted with 3.0 mL bacteriostatic water. Published study references, clinical-study contexts, and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Tesamorelin is commonly discussed in research involving GHRH analog activity, growth hormone release, IGF-1 pathway response, visceral adiposity, and metabolic marker documentation.
Study Limitations
Tesamorelin has an approved-drug context for a specific population and indication, but research-chemical vial references should not be treated as interchangeable with prescription products or clinical protocols.
Safety Considerations
Research discussion should account for glucose monitoring, IGF-1 response, hypersensitivity risk, contraindication screening, and formulation-specific handling considerations.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.